Santander

BIG PHARMAS, NOT SUCH AN ALL-WEATHER INVESTMENT

25/06/20 -"This story was first issued on 15-06-2020. ‘Valuation Wise’ takes a rest. Pre-COVID-19, holding Big Pharmas (seven issuers, €940bn market cap) would not make a big difference ..."

PDF page sample
Pages
64
Language
English
Published on
25/06/20
Download
You may also be interested by these reports :
12/11/25
ABN delivered another mediocre quarter, with a low-quality beat driven by LLP releases, while revenues disappointed and costs rose, pushing C/I to ...
10/11/25
In our previous teaser on ING (REDUCE; Netherland), we outlined how the pan European retail banking giant’s focus on client deposits growth increased ...
07/11/25
The group posted a good set of third-quarter results, above management and consensus expectations, but largely in line with 2026 standalone guidance ...
06/11/25
Operating performance in 9M25 exceeds our estimates –TP increased to CHF 147 and rating upgraded to Add

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO